GSK (GSK) Shares Up Significantly Since Jim Cramer Said to Buy it “and Put it Away”

Group 1 - GSK has entered the weight loss market by acquiring 35Pharma and introducing the HS235 drug for fat-selective weight loss and muscle mass preservation [1] - GSK's shares have increased by 38% over the past year, reflecting positive market sentiment since Jim Cramer recommended the stock in March 2025 [1] - The company reported fourth-quarter earnings of 8.6 billion pounds in revenue and 25.5 pence in earnings per share, surpassing analyst expectations [1] Group 2 - Following the third-quarter earnings report, GSK raised its 2025 revenue growth estimates from 3%-5% to 6%-7%, with reported revenue of 8.6 billion pounds and earnings per share of 55 pence [1] - Jim Cramer praised GSK, highlighting its low price-to-earnings ratio and 4% yield, indicating it as a strong investment opportunity [1]